InVasc Therapeutics In-Licenses BioLink Patent Application for Alpha Lipoic Acid Salt for Use in Chronic Kidney Disease

ATLANTA--(BUSINESS WIRE)--InVasc Therapeutics, Inc., a biopharmaceutical company focused on chronic kidney and cardiometabolic diseases, announced today the execution of an in-license agreement for a patent application related to a salt of an alpha lipoic acid derivative from BioLink Life Sciences, Inc. InVasc is developing a drug with alpha lipoic acid in combination with an antihypertensive for the treatment of chronic kidney disease.